ProQR Therapeutics NV (NASDAQ:PRQR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.

According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “

A number of other analysts have also recently commented on PRQR. Leerink Swann reaffirmed a “buy” rating on shares of ProQR Therapeutics NV in a research report on Thursday, August 18th. Janney Montgomery Scott began coverage on ProQR Therapeutics NV in a research report on Wednesday, September 28th. They set a “neutral” rating and a $7.00 price target for the company. Finally, JMP Securities reaffirmed a “buy” rating on shares of ProQR Therapeutics NV in a research report on Tuesday, September 6th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $14.13.

Analyst Recommendations for ProQR Therapeutics NV (NASDAQ:PRQR)

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Shares of ProQR Therapeutics NV (NASDAQ:PRQR) opened at 6.45 on Wednesday. The stock’s market cap is $150.58 million. ProQR Therapeutics NV has a 52-week low of $3.48 and a 52-week high of $16.23. The company’s 50 day moving average price is $6.46 and its 200 day moving average price is $5.45.

ProQR Therapeutics NV (NASDAQ:PRQR) last issued its quarterly earnings results on Wednesday, August 17th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.00. On average, analysts anticipate that ProQR Therapeutics NV will post ($2.09) earnings per share for the current year.

An institutional investor recently raised its position in ProQR Therapeutics NV stock. Sabby Management LLC increased its stake in shares of ProQR Therapeutics NV (NASDAQ:PRQR) by 276.0% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 149,934 shares of the biopharmaceutical company’s stock after buying an additional 110,063 shares during the period. Sabby Management LLC owned about 0.64% of ProQR Therapeutics NV worth $732,000 at the end of the most recent quarter. Institutional investors and hedge funds own 39.21% of the company’s stock.

ProQR Therapeutics NV Company Profile

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

5 Day Chart for NASDAQ:PRQR

Get a free copy of the Zacks research report on ProQR Therapeutics NV (PRQR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ProQR Therapeutics NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics NV and related companies with's FREE daily email newsletter.